Clinical trials: Transplant Recipient
Kidney Transplant Rejection, Antibody-mediated Rejection
Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection
Patients after kidney transplantation who develop donor-specific antibodies (DSA) are at high risk for antibody-mediated rejection (ABMR).
- Conditions
- Kidney Transplant Rejection, Antibody-mediated Rejection, Kidney Transplant Failure
- Trial name
- cfDNA-DSA (NCT04897438)
- Testing
- Kidney allograft biopsy depending on donor-derived cell-free DNA levels
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Kidney Transplant, Kidney Transplant Failure
Dapagliflozin in Living-Donor Kidney Transplant Recipients
This randomized, open-label, single-center clinical trial aims to evaluate the effect of dapagliflozin on kidney allograft function in adult recipients of a first living-donor kidney transplant.
- Trial name
- DAPA-GRAFT (NCT07555106)
- Testing
- Dapagliflozin (10mg Tab), Standard of Care
- Where
- Mexico
- Volunteers
- 54 people
- Sponsor
- University of Guadalajara
Transplantation Infection, Cytomegalovirus Infection
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals.
- Trial name
- EVERCMV (NCT02328963)
- Testing
- Everolimus, mycophenolic acid
- Where
- 9 sites in France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Bordeaux
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
This phase I trial studies the side effects of Nozin in preventing respiratory viral infections in patients undergoing stem cell transplant.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Solid Neoplasm
- Trial name
- NCT04060849
- Testing
- Nozin, Best Practice
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Fred Hutchinson Cancer Center
Cardiovascular Diseases, Diabetes Mellitus
Improving Medication Safety and CVD Risk Factor Control in Kidney Transplant Recipients
There is a lack of data analyzing the influence of Cardio-vascular Diseases (CVD) risk factor control on graft survival disparities in Black transplant recipients.
- Conditions
- Cardiovascular Diseases, Diabetes Mellitus, Medication Adherence
- Trial name
- NCT02763943
- Testing
- Pharmacist-led, technology enabled education intervention
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Kidney Transplant; Complications
The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients
This is a single-center, prospective, open-label, randomized, cross-over study.
- Trial name
- NCT03301558
- Testing
- Low dose sodium bicarbonate, High dose sodium bicarbonate
- Where
- Austria
- Sponsor
- Prim. Priv. Doz. Dr. Daniel Cejka
Kidney Disease, Chronic, Medication Adherence
PLATO - Medication Adherence in Transplant Recipients
Non-adherence with immunosuppressant drugs is a major reason for premature kidney transplant failure. Currently, patient education and compliance aids (e.g bubble packing) are commonly used to assist patients.
- Conditions
- Kidney Disease, Chronic, Medication Adherence, Renal Disease, Kidney Rejection Transplant
- Trial name
- NCT04078750
- Testing
- Tailored medication adherence plan
- Where
- 2 sites in Canada
- Volunteers
- 99 people
- Sponsor
- University of British Columbia
Graft Versus Host Disease, Hematopoietic Cell Transplantation Recipient
Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
This pilot clinical trial studies how well a gluten free diet works in preventing graft versus host disease in patients who are undergoing a donor stem cell transplant.
- Trial name
- NCT03102060
- Testing
- Dietary Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rutgers, The State University of New Jersey
Ulcerative Colitis
Fecal Transplantation Using a Diet for Donor and Recipient in Refractory Colitis
Changing the microbiota has become the most intriguing target for intervention in inflammatory bowel disease (IBD). Dietary therapy is successful in mild to moderate Crohn's disease and may be effective in mild to moderate…
- Trial name
- NCT02734589
- Testing
- Fecal transplantation, Unique novel Diet for UC and Unique novel Diet for the donor + FMT, Unique novel Diet for UC
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 54 people
- Sponsor
- Wolfson Medical Center
EBV Infection, EBV Viremia
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
Transplant recipients are treated with immunosuppressive drugs to avoid rejection of the transplanted organ. As the medication impairs the immune response, it also increases the risk of serious infections and cancer in transplant…
- Conditions
- EBV Infection, EBV Viremia, Epstein-Barr Virus Associated Lymphoproliferative Disorder, Post-transplant Lymphoproliferative Disorder
- Trial name
- EVITA (NCT04189835)
- Testing
- EBV DNA in whole blood and plasma
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 509 people
- Sponsor
- University of Aarhus
Transplant Complication, CMV
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant…
- Trial name
- NCT06034925
- Testing
- Maribavir, Valganciclovir
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Medical University of South Carolina
Chronic Kidney Disease
Development and Effects of a Structural Education Program in Adult Kidney Transplant Recipients
Kidney transplantation is the treatment of choice for patients with end-stage renal disease. The purpose of this randomized and controlled study is to evaluate the efficacy of a structured education program for adult kidney…
- Trial name
- NCT01630824
- Testing
- Structured education program
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- University of Jena
Portosystemic Shunt
To Compare the Outcome of Temporary Portocaval Shunt During Recipient Hepatectomy Versus No Shunt in Adult Elective Live Donor Liver Transplantation.
Temporary portocaval Shunt during recipient hepatectomy improves intra operative parameters and morbidity in LDLT recipients
- Trial name
- NCT05385120
- Testing
- Temporary Portocaval Shunt
- Volunteers
- 40 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Transplantation, Infection
Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids
Systemic infection is still a major concern in young children with liver transplantation. The approach of this study is to reduce the risk of systemic infections by avoiding intraoperative steroids (another class of…
- Trial name
- NCT00149890
- Testing
- Basiliximab, Cyclosporine/cyclosporine microemulsion, Steroid
- Where
- Germany
- Volunteers
- 77 people
- Sponsor
- Novartis
Renal Transplantation
Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients
The purpose of this study is to evaluate if the delayed administration of everolimus could reduce the everolimus associated "anti-proliferative complications" (e.g.
- Trial name
- NCT00154297
- Testing
- Everolimus (RAD001)
- Where
- Switzerland
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Donor to Recipient Gender Mismatch in LDLT
Donor Gender Effect on Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant
Liver transplantation (LT) represents the gold-standard therapy for the treatment in case of dreadful liver pathologies . It is thus a main concern to optimize the results in terms of post-LT survivals.
- Trial name
- NCT04068363
- Testing
- non interventional
- Where
- Egypt
- Volunteers
- 342 people
- Sponsor
- Ain Shams University
Cytomegalovirus (CMV)
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after…
- Trial name
- NCT02927067
- Testing
- Maribavir, Valganciclovir
- Where
- 129 sites in United States, Australia and 21 more
- Volunteers
- 553 people
- Sponsor
- Shire
Renal Transplant Recipients
Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk
To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match, receiving immunosuppressive therapy with A) Zenapax®…
- Trial name
- NCT00138970
- Testing
- Zenapax®, CellCept® and prednisolone, Sandimmun Neoral®, CellCept® and prednisolone
- Volunteers
- 70 people
- Sponsor
- University of Oslo School of Pharmacy
Hypophosphatemia, Kidney Transplantation
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
- Trial name
- NCT06824454
- Testing
- Dipyridamole 75 MG
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Stanford University
Cytomegalovirus Infections, Heart Transplantation
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age
This open label study will assess the pharmacokinetics and the safety and tolerability of Valcyte (valganciclovir) powder for oral solution in neonatal and infant heart transplant patients < 4 months of age.
- Trial name
- NCT01165580
- Testing
- valganciclovir [Valcyte]
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.